Ariela Katz

Articles

Triplet Therapy With Selinexor Tested in Myeloma

December 4th 2017

Selinexor, a novel drug that targets a tumor-suppressor “cargo” protein mechanism, is being investigated in patients with relapsed/refractory multiple myeloma who have received 1 to 3 prior treatment regimens.

Neoadjuvant Chemotherapy Significantly Improves OS for Low-Risk, Basal Bladder Cancer

December 2nd 2017

Treatment with neoadjuvant chemotherapy prior to radical cystectomy significantly improved overall survival compared with cystectomy alone for patients with the basal subtype of muscle-invasive bladder cancer.

Sensitivity, Resistance of Molecular Subtypes in Prostate Cancer Identified Through Drug Response Scores

December 2nd 2017

Prostate cancer has recently been recognized as a genomically heterogeneous disease with subtypes similar to breast or ovarian cancers.

Checkpoint Inhibitors Hold Promise for BCG-Unresponsive NMIBC

December 1st 2017

The established efficacy of single-agent checkpoint inhibition for metastatic urothelial carcinoma along with molecule expression analyses suggests that PD-1/PD-L1 inhibition could hold promise for patients with non-muscle invasive bladder cancer, particularly those unresponsive to Bacillus Calmette-Guérin.

MRI, PCA3 Tests Are Reliable Indicators of Prostate Biopsy Positivity

December 1st 2017

Both magnetic resonance imaging and prostate cancer antigen 3 tests can predict a positive prostate biopsy and are helpful in identifying high-risk prostate cancer.

Immunotherapy Combinations on the Rise for RCC

November 30th 2017

The combination of PD-1 or PD-L1 inhibitors with existing frontline therapies could represent a superior approach for some treatment-naïve patients with renal cell carcinoma.

Incentivizing the Lower-Cost Decision: LUGPA Believes It Knows How

November 19th 2017

A newly proposed urology-specific alternative payment model could save up to 37% on costs of care, partly by giving physicians incentives to pursue active surveillance rather than active intervention, according to the Large Urology Group Practice Association.

PARP Inhibitor Tested in mCRPC

November 17th 2017

Rucaparib, a drug approved for the treatment of ovarian cancer, might also be used to treat patients with metastatic castration-resistant prostate cancer.

New Diagnostic Assays in the Works to Test for TRK Fusions

November 16th 2017

Oncogenic fusions involving TRK proteins have been implicated in various cancer types, prompting clinical development of therapies targeting the aberrations across histologies rather than their body site of origin.

EZH2 Inhibitor Tested as Epigenetic Option in NHL Types

October 26th 2017

Tazemetostat, a small molecule that targets epigenetic activity of the EZH2 gene, is being investigated as a treatment option for patients with relapsed or refractory diffuse large B-cell lymphoma or follicular lymphoma.

Novel Alkylating Agent Defies Mechanisms of Resistance in GBM Tumors

October 11th 2017

VAL-083, a novel alkylating agent that has demonstrated potency against brain tumor cells and can overcome resistance associated with methylguanine methyltransferase (MGMT), is being investigated in patients with glioblastoma multiforme or gliosarcoma who had progressive disease during or after treatment with bevacizumab.

PEGPH20 Offers New Mechanism for Attacking Pancreas Tumors

September 29th 2017

PEGPH20 (pegvorhyaluronidase alfa), a novel formulation of a naturally occuring enzyme, is being investigated as a biomarker-driven treatment for patients with advanced pancreatic cancer.

AKT Inhibitor May Promote Better Responses to Abiraterone in mCRPC

September 7th 2017

Ipatasertib is being investigated in patients with metastatic castration-resistant prostate cancer as a method of simultaneously blocking a resistance mechanism to hormone therapy and improving responses to abiraterone.

Angiogenesis Inhibitor Tested in Mesothelioma Trial

August 21st 2017

Nintedanib, an angiogenesis inhibitor, is being investigated as a first-line treatment for patients with unresectable malignant pleural mesothelioma (MPM).

AR-V7 Biomarker Test Remains on the Wish List for CRPC

August 20th 2017

The use of biomarkers in genitourinary cancers offers exciting potential in understanding which patients may do better with androgen-targeting therapies.

First-of-Its-Kind Multidisciplinary Guidelines for MIBC Treatment

August 14th 2017

A first-ever collaboration between the American Urological Association and other prominent urological groups has created a multidisciplinary set of guidelines on treating patients with nonmetastatic muscle-invasive bladder cancer (MIBC).

Genomic Landscape of Prostate Cancer Aligns With Breast Cancer Subtypes

August 4th 2017

A comparison of the genomic risk profiles of patients with low-risk prostate cancer who are candidates for active surveillance against higher-risk patients, discovered that substantial genomic heterogeneity exists among patients with prostate cancer.

XPO1 Inhibitor Offers Novel Mechanism for Treating Penta-Refractory Myeloma

August 3rd 2017

Selinexor (KPT-330), a small-molecule inhibitor with a novel mechanism of action, is being investigated in patients with multiple myeloma who have become refractory to the many new options that have been introduced in recent years for patients with the malignancy.

Epigenetic Assay Could Spare Patients From Additional Biopsies for Prostate Cancer

July 17th 2017

A new test that can detect the existence of tumor activity is gaining credibility as a means of confirming the results of prostate biopsies, which have the potential to miss tumor cells.

Myeloma Trial Explores Optimal Induction, Maintenance Regimens

July 17th 2017

Two combination regimens anchored by different proteasome inhibitors are being compared in a national clinical trial for patients with newly diagnosed symptomatic multiple myeloma that also seeks to evaluate the ideal duration of lenalidomide (Revlimid) maintenance therapy.